Stocktoria

Genenta Science S.p.A. GNTA

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-12-15 · LEI

Genenta Science S.p.A. financials (annual)

Revenue
202020212022202320242025
Net income
-$5.6M -$5.5M -$8.5M -$11.6M -$8.9M -$6.5M 202020212022202320242025
Free cash flow
-$6.1M -$7.0M -$7.4M -$11.2M -$6.2M -$6.9M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
R&D expense$2.7M$4.8M$6.5M$5.3M$3.4M$4.7M
Operating income-$6.6M-$9.8M-$11.7M-$11.0M-$5.7M-$5.6M
Net income-$6.5M-$8.9M-$11.6M-$8.5M-$5.5M-$5.6M
EPS (diluted)$-0.33$-0.49$-0.64$-0.47$-0.37
Operating cash flow-$6.9M-$6.2M-$11.2M-$7.4M-$7.0M-$6.0M
Free cash flow-$6.9M-$6.2M-$11.2M-$7.4M-$7.0M-$6.1M
Cash & equivalents$5.5M$4.6M$3.7M$29.8M$25.7M$15.5M
Total assets$31.9M$14.8M$22.3M$33.4M$40.0M$17.5M
Shareholders' equity$21.8M$12.5M$20.4M$31.1M$38.9M$15.2M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.